Overview
China chemical and pharmaceutical maker's interim revenue grew 20% yr/yr
Net profit for the period rose over 300%, driven by higher gross profit
Outlook
Company did not provide specific financial guidance for future quarters or the full year
Result Drivers
SEGMENT GROWTH - Revenue increased in Methylamine Industry Series, Goldenhighway New Materials, and Advanced Materials Intermediates Series, driven by higher sales volumes, expanded market share, and new trading products
PRICE AND VOLUME EFFECTS - Higher average selling prices and increased sales volumes of choline chloride and betaine, as well as polymeric MDI, supported gross profit growth
FULL PRODUCTION RESUMPTION - Advanced Materials Intermediates Series benefited from the resumption of full production capacity and new trading products such as isooctanol
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
RMB 2.23 bln
H1 Net Income Attributable
RMB 29.40 mln
Reuters Recommended Reads
Aug 25 - China's Sinofert H1 revenue rises 10.6% on policy support
Aug 24 - China's Asymchem H1 revenue rises on strength in emerging businesses
Aug 24 - Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .